Compound LawsREAL-TIME LEGAL INTELLIGENCE
Home / Compounds / Ibogaine / New Mexico

Is Ibogaine Legal in New Mexico? (2026)

Illegal

As of November 12, 2026, Ibogaine is illegal to sell (federally scheduled; state law on file reads illegal) in New Mexico. Schedule I federally (21 CFR 1308.11(d)(21)); 2026 research push, no approval. Controlling source: 16.19.20.65(E) NMAC, Schedule I hallucinogenic substances (Board of Pharmacy).

Verified November 12, 2026 (hash check) · confidence: confirmed

Is Ibogaine Legal? Every state and federal law

New Mexico Ibogaine ban status: ban in force

QuietNo pending legislation, deadlines or enforcement actions on file for Ibogaine in New Mexico.
Federal
Schedule I federally (21 CFR 1308.11(d)(21)); 2026 research push, no approval (effective 1971-05-01). State-law reading underneath: Illegal.
Rule type
permanent
Tier
Schedule I
Schedule
schedule 1

What the record says

New Mexico Schedule I names ibogaine at 16.19.20.65(E)(25) NMAC under a lead-in reaching any material, compound, mixture or preparation which contains any quantity of it, so iboga root bark containing ibogaine is captured; Tabernanthe iboga is not named. The statute (NMSA 1978 Sec. 30-31-6(C), as amended by Laws 2025, ch. 73) lists the same hallucinogens under a lead-in reaching any material, compound, mixture or preparation that contains any quantity of them. No New Mexico ibogaine research or funding law was found for 2025 or 2026, and noribogaine is not named. See the federal page.

Controlling language, verbatim

HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical, positional, and geometric isomers). ... (25) Ibogaine;

Source of excerpt

Citations

  1. 16.19.20.65(E) NMAC, Schedule I hallucinogenic substances (Board of Pharmacy) (New Mexico State Records Center and Archives (NMAC), 2026-10-31) PRIMARYOFFICIAL
  2. Laws 2025, ch. 73 (SB 219), Sec. 13 amending NMSA 1978 Sec. 30-31-6 (Schedule I) (New Mexico Legislature, 2026-10-31)OFFICIAL
  3. SB 219 (2025) legislation page: chaptered, Laws 2025, ch. 73 (New Mexico Legislature, 2026-10-31)OFFICIAL

Where Ibogaine stands across the country

LegalRestrictedGray areaIllegalNot yet verified

Among New Mexico's 5 neighbors, Arizona, Colorado, Oklahoma, Texas and Utah are illegal, the same posture as New Mexico.

Open the interactive map · Every compound in New Mexico · Where Ibogaine is banned · Embed this map

Federal posture

Federally scheduled or prohibited. Schedule I federally (21 CFR 1308.11(d)(21)); 2026 research push, no approval Federal detail

Verbatim law on file for New Mexico

9 instruments on file for this compound’s framework in New Mexico; 3 of 3 citations above are official sources. Each text carries its source and a fingerprint that changes when the law does.

16.19.20.65 NMAC (Board of Pharmacy, Schedule I), hallucinogenic substances · 16.19.20.65 NMAC (Board of Pharmacy, Schedule I), hallucinogenic substancesOFFICIAL
Instrument
16.19.20.65 NMAC (Board of Pharmacy, Schedule I), hallucinogenic substances
Source
https://www.srca.nm.gov/parts/title16/16.019.0020.html
Retrieved
2026-10-08
Fingerprint
d080906b38ee8437
16.19.20.65 SCHEDULE I: A. Section 30-31-6 NMSA 1978, schedule I shall consist of the following drugs and other substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this section; OPIOIDS , unless specifically exempt or unless listed in another schedule, any of the following opioids, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. (1) Acetylmethadol; (2) Allylprodine ; (3) Alphacetylmethadol ; (4) Alphameprodine; (5) Alphamethadol ; (6) Alpha-methyl fentanyl; (7) Benzethidine ; (8) Betacetylmethadol; (9) Betameprodine ; (10) Betamethadol ; (11) Betaprodine ; (12) Clonitazene ; (13) Desmethyltramadol ; (14) Dextromoramide ; (15) Diampromide ; (16) Diethylthiambutene ; (17) Dimethylthiambutene ; (18) Difenoxin ; (19) Dimenoxadol ; (20) Dimepheptanol ; (21) Dimethylthiambutene ; (22) Dioxaphetyl Butyrate; (23) Dipipanone; (24) Ethylmethylthiambutene; (25) Etonitazene; (26) Etoxeridine; (27) Furethidine; (28) Hydroxypethidine ; (29) Isotonitazene ; (30) Ketobemidone; (31) Levomoramide; (32) Levophenacylmorphan; (33) Morpheridine; (34) Noracymethadol; (35) Norlevorphanol ; (36) Normethadone; (37) Norpipanone; (38) Phenadoxone; (39) Phenampromide; (40) Phenomorphan; (41) Phenoperidine; (42) Piritramide; (43) Proheptazine ; (44) Properidine ; (45) Propiram ; (46) Racemoramide; (47) Tilidine ; (48) Trimeperidine (49) U-48800; (2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide, monohydrochloride; (50) U-49900; (trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide; (51) Beta-Hydroxy-3-Methylfentanyl; (52) 3-Methylthiofentanyl; (53) Acetyl -Alpha- Methyl fentanyl ; (54) Alpha- Methylthiofentanyl ; (55) Beta- hydroxfentanyl ; (56) Para-Fluoro fentanyl ; (57) Thiofentanyl ; (58) Acetyl fentanyl ; (59) Butyryl fentanyl ; (60) Betahydroxythiofentanyl ; (61) Furanyl fentanyl ; (62) AH-7921; ( 3,4-dichloro-N-[(1- dimethylamino) cyclohexylmethyl ] benzamide ); (63) U47700; (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide); (64) MT-45; (1-(4- Nitrophenylethyl)piperidylidene -2-(4-chlorophenyl)sulfonamide); (65) W-15; (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide); (66) W-18; (1-(4- Nitrophenylethyl)piperidylidene -2-(4-chlorophenyl)sulfonamide); (67) U-50488; (2-(3,4-dichlorophenyl)-N- methyl -N-[(1R,2R)-2-pyrrolidin-1- ylcyclohexyl ] acetamide ); (68) U50488H; (( -)( trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny) cyclo - hexyl]benzeneacetamide). (69) Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of isomers, esters and ethers. Fentanyl-related substance means any substance, unless specifically exempted or unless listed in another schedule, that is structurally related to fentanyl by one or more of the following modifications: (a) replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle; (b) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups; (c) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups; (d) replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or (e) replacement of the N-propionyl group by another acyl group; or (f) any combination of the above substances include, but are not limited to, the following substances: (reserved) (70) Acryl Fentanyl; (71) 4F-butyrfentanyl; (72) 4-methoxybutyrfentanyl; (73) Fluorobutyrfentanyl ; (74) Fluorofentanyl ; (75) FIBF; (Para Fluoro Isobutyryl Fentanyl); (76) Cyclopropyl fentanyl; (77) Thiofuranyl fentanyl (Thiophene fentanyl); (78) 3-methylfentanyl (N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidyl)-N- phenylpropanamide , its optical and geometric isomers, salts and salts of isomers; (79) crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide ); (80) valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylpentanamide ); (81) N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2′-fluoro ortho- fluorofentanyl ; 2′-fluoro 2-fluorofentanyl); (82) N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4′-methyl acetyl fentanyl); (83) beta-phenyl fentanyl or N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (β′-phenyl fentanyl; beta′-Phenyl fentanyl; 3-phenylpropanoyl fentanyl); (84) beta-methyl fentanyl or N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (β-methyl fentanyl); (85) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho- fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl); (86) (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl ; 2-methyl acetylfentanyl ); (87) 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl ; 2-methyl methoxyacetyl fentanyl); (88) N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para- methylfentanyl ; 4-methylfentanyl); (89) N-(1-phenethylpiperidin-4-yl)-N- phenylbenzamide (phenyl fentanyl; benzoyl fentanyl); (90) N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide ( thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl); (91) Ethyl (1-phenethylpiperidin-4- yl )(phenyl)carbamate (fentanyl carbamate); (92) N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide (ortho- fluoroacryl fentanyl); (93) N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl) isobutyramide (ortho- fluoroisobutyryl fentanyl); (94) N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2- carboxamide (para-fluoro furanyl fentanyl); (95) Cyclopentyl fentanyl; (96) Isobutyryl fentanyl; (97) Para -chloroisobutyryl fentanyl; (98) Para -methoxybutyryl fentanyl ; (99) Para -fluorobutyryl fentanyl ; (100) Ocfentanil ; (101) Ortho- Fluorofentanyl ; (102) Tetrahydrofuranyl Fentanyl ; (103) Methoxyacetyl Fentanyl ; (104) 4-Fluoroisobutyryl Fentanyl ; (105) Para- Fluorofentany;l (106) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)- N,N -diethylethan-1- amine); (107) Etodesnitazene ; etazene (2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)- N,N -diethylethan-1- amine); (108) Metonitazene (N, N -diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 H -benzimidazol-1- yl)ethan -1-amine); (109) Flunitazene (N, N -diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1 H -benzimidazol-1- yl)ethan -1-amine); (110) Metodesnitazene (N,6 N -diethyl-2-(2-(4-methoxybenzyl)-1 H -benzimidazol-1- yl)ethan -1-amine); (111) Protonitazene (N, N -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H -benzimidazol-1- yl)ethan -1-amine); (112) Brorphine (1-(1-(1-(4- bromophenyl) ethyl )piperidin-4-yl)-1,3-dihydro-2 H - benzo [ d ]imidazol-2-one); (113) Zipeprol (1-methoxy-3-[4-(2-methoxy-2- phenylethyl)piperazin-1-yl]-1- phenylpropan-2-ol). B. OPIUM DERIVATIVES: Unless specifically exempt or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation. (1) Acetorphine ; (2) Acetyl dihydrocodeine ; (3) Benzyl morphine; (4) Codeine methylbromide ; (5) Codeine -N- Oxide; (6) Cyprenorphine ; (7) Desomorphine ; (8) Dehydro morphine; (9) Etorphine; (10) Heroin ; (11) Hydromorphinol ; (12) Methyldesorphine ; (13) Methyldihydromorphine ; (14) Morphine methylbromide ; (15) Morphine methylsulfonate ; (16) Morphine-N- Oxide; (17) Myrophine ; (18) Nicocodeine ; (19) Nicomorphine ; (20) Normorphine ; (21) Pholcodine; (22) Thebacon ; (23) Drotebanol; (24) 6AM; (6-acetylmorphine). C. STIMULANTS: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers. (1) Fenethylline; (2) N- ethylamphetamine ; (3) cis-4-methylaminorex; (4) N, N-dimethylamphetamine; (5) (BZP), 1-benzylpiperazine; N-benzylpiperazine; (6) (DCPP); 2,3-dichlorophenylpiperazine; (7) (DBZP); dibenzylpiperazine ; (8) (MBZP); methylbenzylpiperazine ; (9) ( mCPP ); meta- chlorophenylpiperazine ; (10) (MDBZP); methylenedioxybenzylpiperazine; (11) ( meOPP ); para- methoxyphenylpiperazine ; (12) ( pCPP ); para- chlorophenylpiperazine ; (13) ( pFPP ); para- fluorophenylpiperazine ; (14) (2-DPMP), desoxypipradrol ; 2-diphenylmethylpiperidine; (15) D2PM, diphenylprolinol ; diphenyl-2-pyrrolidinemethanol; (16) HDMP-28; methylnaphthidate ; (17) Nocaine , (+)-CPCA; 3α-carbomethoxy-4β-(4-chlorophenyl)-N- methylpiperidine ; (18) BTQ or butyltolylquinuclidine ; (2-Butyl-3-(p-tolyl)quinuclidine; (19) Methiopropamine ; (N-methyl-1- (thiophen-2-yl)propan-2-amine); (20) Mesocarb ; (N-phenyl-N′ -(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-yl) carbamimidate ); (21) Amineptine (7- [(10,11-dihydro-5H-dibenzo[ a,d ]cyclohepten-5- yl )amino] heptanoic acid ); (22) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4- methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5- (4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine). D. DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: (1) Mecloqualone; (2) Methaqualone; (3) Benzodiazepines; (a) Bromazepam; (b) Camazepam; (c) Cloxazolam; (d) Delorazepam; (e) Ethylloflazepate; (f) Fudiazepam; (g) Flunitrazepam; (h) Haloxazolam; (i) Ketazolam; (j) Loprazolam; (k) Lormetazepam; (l) Medazepam; (m) Nimetazepam; (n) Nitrazepam; (o) Nordiazepam; (p) Oxazolam; (q) Phenazepam (r) Pinazepam; (s) Tetrazepam; (t) Flubromazepam; (u) Diclazepam ; (v) Etizolam ; (w) Flualprazolam ; (x) Clonazolam ; (y) Flubromazolam ; (z) Bromazolam (4) Gamma hydroxybutyric acid and any chemical compound that is metabolically converted to GHB; (5) G amma butyrolactone and any chemical compound that is metabolically converted to GHB; (6) 1–4 butane diol and any chemical compound that is metabolically converted to GHB (7) GHV or 4-methyl-GHB; γ- hydroxyvaleric acid; (8) GVL; γ- valerolactone ; (9) MMQ; methylmethaqualone; (10) MBQ; mebroqualone. E. HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical, positional, and geometric isomers). (1) 3,4 -methylenedioxy amphetamine; (2) 5 - methoxy - 3,4-methylenedioxy amphetamine; (3) 3,4,5 -trimethoxy amphetamine; (4) Bufotenine; (5) DET; ( Diethyltryptamine ); (6) DMT; (Dimethyltryptamine); (7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine); (8) Lysergic acid amide; (9) Lysergic acid diethylamide ; (10) Mescaline; (11) Peyote; (12) N-ethyl-3-piperidyl benzilate ; (13) N-methyl-3-piperidyl benzilate ; (14) Psilocybin ; (15) Psilocyn ; (16) Parahexyl ( synthetic analog of delta‑9‑tetra­hydrocannabinol ); (17) 2, 5 - dimethoxyamphetamine ; 2, 5-DMA; (18) 4-bromo-2, 5-dimethoxy- amphetamine; 2, 5-DMA; (19) PMA; 4-methoxyamphetamine; (20) PCE; (Ethylamine N-ethyl-1-phenylcyclohexylamine); (21) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine ( PCPy ), (PHP) analog of the drug phencyclidine; (22) Thiophene (analog of phencyclidine) TCP or TPCP; (23) Alpha- ethyltryptamine ; (24) 2, 5-dimethoxy-4-ethylamphet-amine; (25) Ibogaine; (26) 2C-T-7; (2,5-dimethoxy-4-(n)- propylthiophenethylamine ); (27) AMT; (Alpha-methyltryptamine); (28) 5-MeO-DIPT; (5-methoxy-N,N-diisopropyltryptamine); (29) 25B-NBOMe; (2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine ); (30) 25C-NBOMe; (2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine); (31) 25I-NBOMe; (2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine ). (32) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity. Substances include but are not limited to: (a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol); (b ) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol); (c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoy)]indole); (d ) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole); (e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran; (f ) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole); (g ) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl) methanone ; (h ) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole); ( i ) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole; (j ) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); (k ) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole); (l ) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole); (m ) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole); (n ) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone; (o ) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl )-1-naphthalenylmethanone); (p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation; ( i ) naphthoylindoles : any compound containing a 3-(1- naphthoyl ) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201; (ii) naphthylmethylindoles : any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199; (iii) naphthoylpyrroles : any compound containing a 3-(1- naphthoyl ) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307; (iv) naphthylmethylindenes : any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176; (v) phenylacetylindoles : any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8; (vi) cyclohexylphenols : any compound containing a 2-(3- hydroxycyclohexyl ) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490; (vii) benzoylindoles : any compound containing a 3-(benzoyl) [ 5 ] OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241 ; (q) UR-144 1-(pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone ; (r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone; (s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide; (t) QUPIC; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate; (u) 5-fluoro-PB 22; 5F-PB22; Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate; (v) AB- FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide; (w) ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine; (x) AB-CHMINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (y) AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; (z) THJ-2201; [1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone ; (aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate; ( bb ) 5-fluoro ABICA: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; (cc) FUB-144 or FUB-UR-144; [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; (dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide; (ee) FUB-PB-22; Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate; (ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide); (gg) AMB-FUBINACA or FUB-AMB ( methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate); (hh) 5-fluoro-AMB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester); (ii) 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl ester); (jj) Bk-DMBDB or dibutylone; 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one; (kk) MMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate; (ll) MDMB-CHMICA; methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; (mm) NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; (nn) 5-Fluoro-AKB48 or 5F-APINACA; N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; (oo) 5-Fluoro-ADB; Methyl(S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate; (pp) 5-Fluoro-AMB; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methyl ester; (qq) MAB-CHMINACA; N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cycohexylmethyl)-1H-indazole-3-carboxamide; (rr) SDB-006; N-benxyl-1-pentyl-1H-indole-3-carboxamide; (ss) Cumyl-PINACA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide; (tt) Cumyl-PICA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide ; (uu) 5F-CUMYL-PINACA; SGT-25; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3-carboxamide; (vv) 5F-EDMB-PINACA; Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate; (ww) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA]; (xx) N -(Adamantan-1-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (FUB-AKB48; FUB-APINACA; AKB48 N -(4-fluorobenzyl)); (yy) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, or SGT-78); (zz) methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA or AMB-CHMICA); (aaa) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3- carboxamide (5F-CUMYL-P7AICA) (33) Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to: (a) Salvia divinorum ; (b) Salvinorin A (methyl (2 S ,4a R ,6a R ,7 R ,9 S ,10a S ,10b R )-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2 H -benzo[f]isochromene-7-carboxylate); (34) (4-MEC); 4-methyl-ethylcathinone; (35) (4-EMC); 4-ethyl-methcathinone; (36) Ethcathinone ; 2-ethylamino-1-phenyl-propan-1-one; (37) Ethylone ; 3’,4’-methylenedioxyethcathinone; (38) Bk-MBDB, butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine; (39) (NRG-1), naphyrone ; naphthylpyrovalerone ; (40) Metamfepramone; N,N-dimethylcathinone; (41) Alpha-PPP; alpha-pyrrolidinopropiophenone; (42) (α-PBP); alpha- pyrrolidinobutiophenone ; (43) (MOPPP); 4’-methoxy-alpha-pyrrolidinopropiophenone; (44) (MαPPP); 4’-methyl-α- pyrrolidinopropiophenone ; (45) (MDPPP); 3’,4’-methylenedioxy-alpha-pyrrolidinopropiophenone; (46) (MDPBP); 3’,4’-methylenedioxy-alpha-pyrrolidinobutiophenone; (47) (MPBP); 4’-methyl-α- pyrrolidinobutiophenone ; (48) Alpha-PVP; alpha-pyrrolidinovalerophenone; (49) (MDAI); 5,6-methylenedioxy-2-aminoindane; (50) Buphedrone ; alpha-methylamino-butyrophenone; (51) Eutylone ; beta-keto- ethylbenzodioxolylbutanamine ; (52) beta-keto- ethylbenzodioxolylpentanamine ; (53) beta-keto- methylbenzodioxolylpentanamine ( pentylone ); (54) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus); (55) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA; (56) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-( dimethylamino )ethyl]indole; 5-MeO-DMT; (57) Mephedrone; 4-methylmethcathinone; (58) (MDPV); 3,4-methylenedioxypyrovalerone; (59) (2C-E); 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine ; (60) (2C-D); 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine ; (61) (2C-T-2); 2-[4-( Ethylthio )-2,5-dimethoxyphenyl] ethanamine ; (62) (2C-T4); 2-[4-( Isopropylthio )-2,5-dimethoxyphenyl] ethanamine ; (63) (2C-H); 2-(2,5-Dimethoxyphenyl) ethanamine ; (64) (2C-N); 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine ; (65) (2C-P); 2-(2,5-Dimethoxy-4-(n)- propylphenyl ) ethanamine ; (66) Methylone; 3,4-Methylenedioxy-N-methylcathinone; (67) Aminorex (2-amino-5-phenyl-2-oxazoline); (68) Pentedrone ; (69) 4-FMC or flephedrone ; 4-fluro-N-methylcathinone; (70) (3-FMC); 3-fluro-N-methylcathinone; (71) (3-MMC); 3-methylmethcathinone; (72) (3,4 DMMC); 3,4-Dimethylmethcathinone; (73) (3-MEC); 3-Methyl-N-ethylcathinone; (74) 4-methylbuphedrone or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one (75) (4 MTA); 4-methylthioamphetamine; (76) (5-Me MDA); 5-methyl-3,4-methylenedioxyamphetamine; (77) (6-APB); 6-benzofuran; (78) (PMA); 4-methoxyamphetamine; (79) (2C-B); 2,5-dimethoxy-4-bromophenethylamine; (80) (2C-C); 2,5-dimethoxy-4-chlorophenethylamine; (81) (2C-D); 4-methyl-2,5-dimethoxyphenethylamine; (82) (2C-E, aquarust , cindy ); 2,5-dimethoxy-4-ethylphenethylamine; (83) (2C-G); 3,4-dimethyl-2,5-dimethoxyphenethylamine; (84) (2C-I); 2,5-dimethoxy-4-iodophenethylamine; (85) (2C-T21); 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl] ethanamine ; (86) (2C-B-FLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- yl) ethanamine ; (87) Bromo- DragonFLY or 3C-Bromo-Dragonfly or DOB- Dragonfly ; 1-(4-Bromofuro[2,3-f][1]benzofuran-8- yl)propan -2-amine; (88) (DOB); 2,5-Dimethoxy-4-bromoamphetamine; (89) (DOC); 2,5-Dimethoxy-4-chloroamphetamine; (90) (DOM); 2,5-Dimethoxy-4-methylamphetamine; (91) (TMA2); 2,4,5-trimethoxyamphetamine; (92) (TMA6); 2,4,6-trimethoxyamphetamine; (93) (MDAT); 6,7-methylenedioxy-2-aminotetralin; (94) (4-acetoxy DiPT , ipracetin ); 4-acetoxy-N,N-diisopropyltryptamine; (95) (4-acetoxy DMT, psilacetin ;) O- Acetylpsilocin ; (96) 4-HO MET, metocin ; 4-hydroxy-N-methyl-N-ethyltryptamine; (97) 4-HO MiPT , hats ; 4-hydroxy-N-methyl-N-isopropyltryptamine; (98) 5-MeO-aMT, Alpha-O; 5-methoxy- α - methyltryptamine ; (99) (5-MeO-MiPT); N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine; (100) (DiPT); N,N-diisopropyltryptamine; (101) (DPT); dipropyltryptamine; (102) (5-MeO-DALT); N,N -diallyl-5-methoxytryptamine; (103) (3-MeO PCP); 3-methoxyphencyclidine; (104) (4-MeO PCP); 4-methoxyphencyclidine; (105) (MK-801); dizocilpine; (106) (PCE, perchloroethylene, perchloroethene ), Perc; tetrachloroethylene; (107) (PCE, perchloroethylene, perchloroethene ), Perc; tetrachloroethylene; (108) ( PCPr ); phencyclamine , N-(1-phenylcyclohexyl) propanamine ; (109) (Tenocyclidine); 1-(1-(2-thienyl)cyclohexyl)piperidine (110) (3-MeO PCE); 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl) cyclohexanamine ; (111) (ETH-LAD); 6-ethyl-6-nor-lysergic acid diethylamide; (112 (AL-LAD); 6-allyl-6-nor-LSD; (113) (PRO-LAD); 10-didehydroergoline-8-carboxamide; (114) ((1-(1,3-benzodioxol-5-yl)-2-( ethylamino )pentan-1-one, N- ethylpentylone ); (115) (MPHP), 4´-methyl-alpha-pyrrolidinohexiophenone; (116) 4'-chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP; 4'-chloro-α- pyrrolidinopentiophenone ); (117) 4-methyl-alpha-ethylaminopentiophenone (4-MEAP; 2-( ethylamino )-1-(4-methylphenyl)pentan-1-one); (118) Alpha- pyrrolidinoheptaphenone (PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); (119) Alpha- pyrrolidinohexanophenone (α-PHP; α- pyrrolidinohexanophenone ; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (120) N- ethylhexedrone (α- ethylaminohexanophenone ; 2-( ethylamino )-1- phenylhexan-1-one); (121) Methoxetamine; 2-( ethylamino )-2-(3-methoxyphenyl)cyclohexan-1-one; 2-(3-methoxyphenyl)-2-(N- ethylamino )cyclohexanone; MXE). F. Any material, compound, mixture or preparation which contains any quantity of the following substances. (1) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers; (2) (MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its optical isomers, salts, and salts of isomers; (3) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and salts of isomers; (4) Cathinone; (5) Methcathinone; (6) Tianeptene ; (7) Para - Methoxymethamphetamine (PMMA) [16.19.20.65 NMAC - Rp 16.19.20.65 NMAC, 6/26/2018; A, 12/17/2019; A, 9/14/2021 ;
16.19.20.65(E) NMAC · Schedule I, hallucinogenic substancesOFFICIAL
Instrument
Schedule I, hallucinogenic substances
Source
https://www.srca.nm.gov/parts/title16/16.019.0020.html
Retrieved
2026-11-06
Fingerprint
46393f93acf35c75
HALLUCINOGENIC SUBSTANCES: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical, positional, and geometric isomers). (1) 3,4 -methylenedioxy amphetamine; (2) 5 - methoxy - 3,4-methylenedioxy amphetamine; (3) 3,4,5 -trimethoxy amphetamine; (4) Bufotenine; (5) DET; ( Diethyltryptamine ); (6) DMT; (Dimethyltryptamine); (7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine); (8) Lysergic acid amide; (9) Lysergic acid diethylamide ; (10) Mescaline; (11) Peyote; (12) N-ethyl-3-piperidyl benzilate ; (13) N-methyl-3-piperidyl benzilate ; (14) Psilocybin ; (15) Psilocyn ; (16) Parahexyl ( synthetic analog of delta‑9‑tetra­hydrocannabinol ); (17) 2, 5 - dimethoxyamphetamine ; 2, 5-DMA; (18) 4-bromo-2, 5-dimethoxy- amphetamine; 2, 5-DMA; (19) PMA; 4-methoxyamphetamine; (20) PCE; (Ethylamine N-ethyl-1-phenylcyclohexylamine); (21) Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine ( PCPy ), (PHP) analog of the drug phencyclidine; (22) Thiophene (analog of phencyclidine) TCP or TPCP; (23) Alpha- ethyltryptamine ; (24) 2, 5-dimethoxy-4-ethylamphet-amine; (25) Ibogaine; (26) 2C-T-7; (2,5-dimethoxy-4-(n)- propylthiophenethylamine ); (27) AMT; (Alpha-methyltryptamine); (28) 5-MeO-DIPT; (5-methoxy-N,N-diisopropyltryptamine); (29) 25B-NBOMe; (2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine ); (30) 25C-NBOMe; (2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine); (31) 25I-NBOMe; (2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine ). (32) Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity. Substances include but are not limited to: (a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol); (b ) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol); (c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoy)]indole); (d ) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole); (e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran; (f ) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole); (g ) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl) methanone ; (h ) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole); ( i ) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole; (j ) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); (k ) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole); (l ) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole); (m ) JWH-210 (1-pentyl-3-(4-ethylnaphthoyl)indole); (n ) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone; (o ) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl )-1-naphthalenylmethanone); (p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation; ( i ) naphthoylindoles : any compound containing a 3-(1- naphthoyl ) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201; (ii) naphthylmethylindoles : any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199; (iii) naphthoylpyrroles : any compound containing a 3-(1- naphthoyl ) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307; (iv) naphthylmethylindenes : any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176; (v) phenylacetylindoles : any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8; (vi) cyclohexylphenols : any compound containing a 2-(3- hydroxycyclohexyl ) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490; (vii) benzoylindoles : any compound containing a 3-(benzoyl) [ 5 ] OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl , cycloalkylethyl , 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241 ; (q) UR-144 1-(pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone ; (r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone; (s) AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide; (t) QUPIC; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate; (u) 5-fluoro-PB 22; 5F-PB22; Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate; (v) AB- FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide; (w) ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamine; (x) AB-CHMINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; (y) AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; (z) THJ-2201; [1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone ; (aa) FDU-PB-22 IUPAC: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate; ( bb ) 5-fluoro ABICA: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; (cc) FUB-144 or FUB-UR-144; [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; (dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide; (ee) FUB-PB-22; Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate; (ff) ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide); (gg) AMB-FUBINACA or FUB-AMB ( methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate); (hh) 5-fluoro-AMB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester); (ii) 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl ester); (jj) Bk-DMBDB or dibutylone; 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one; (kk) MMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate; (ll) MDMB-CHMICA; methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; (mm) NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; (nn) 5-Fluoro-AKB48 or 5F-APINACA; N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; (oo) 5-Fluoro-ADB; Methyl(S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate; (pp) 5-Fluoro-AMB; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methyl ester; (qq) MAB-CHMINACA; N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cycohexylmethyl)-1H-indazole-3-carboxamide; (rr) SDB-006; N-benxyl-1-pentyl-1H-indole-3-carboxamide; (ss) Cumyl-PINACA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide; (tt) Cumyl-PICA; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide ; (uu) 5F-CUMYL-PINACA; SGT-25; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3-carboxamide; (vv) 5F-EDMB-PINACA; Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate; (ww) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA]; (xx) N -(Adamantan-1-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (FUB-AKB48; FUB-APINACA; AKB48 N -(4-fluorobenzyl)); (yy) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, or SGT-78); (zz) methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA or AMB-CHMICA); (aaa) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3- carboxamide (5F-CUMYL-P7AICA) (33) Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to: (a) Salvia divinorum ; (b) Salvinorin A (methyl (2 S ,4a R ,6a R ,7 R ,9 S ,10a S ,10b R )-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2 H -benzo[f]isochromene-7-carboxylate); (34) (4-MEC); 4-methyl-ethylcathinone; (35) (4-EMC); 4-ethyl-methcathinone; (36) Ethcathinone ; 2-ethylamino-1-phenyl-propan-1-one; (37) Ethylone ; 3’,4’-methylenedioxyethcathinone; (38) Bk-MBDB, butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine; (39) (NRG-1), naphyrone ; naphthylpyrovalerone ; (40) Metamfepramone; N,N-dimethylcathinone; (41) Alpha-PPP; alpha-pyrrolidinopropiophenone; (42) (α-PBP); alpha- pyrrolidinobutiophenone ; (43) (MOPPP); 4’-methoxy-alpha-pyrrolidinopropiophenone; (44) (MαPPP); 4’-methyl-α- pyrrolidinopropiophenone ; (45) (MDPPP); 3’,4’-methylenedioxy-alpha-pyrrolidinopropiophenone; (46) (MDPBP); 3’,4’-methylenedioxy-alpha-pyrrolidinobutiophenone; (47) (MPBP); 4’-methyl-α- pyrrolidinobutiophenone ; (48) Alpha-PVP; alpha-pyrrolidinovalerophenone; (49) (MDAI); 5,6-methylenedioxy-2-aminoindane; (50) Buphedrone ; alpha-methylamino-butyrophenone; (51) Eutylone ; beta-keto- ethylbenzodioxolylbutanamine ; (52) beta-keto- ethylbenzodioxolylpentanamine ; (53) beta-keto- methylbenzodioxolylpentanamine ( pentylone ); (54) 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus); (55) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA; (56) 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-( dimethylamino )ethyl]indole; 5-MeO-DMT; (57) Mephedrone; 4-methylmethcathinone; (58) (MDPV); 3,4-methylenedioxypyrovalerone; (59) (2C-E); 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine ; (60) (2C-D); 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine ; (61) (2C-T-2); 2-[4-( Ethylthio )-2,5-dimethoxyphenyl] ethanamine ; (62) (2C-T4); 2-[4-( Isopropylthio )-2,5-dimethoxyphenyl] ethanamine ; (63) (2C-H); 2-(2,5-Dimethoxyphenyl) ethanamine ; (64) (2C-N); 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine ; (65) (2C-P); 2-(2,5-Dimethoxy-4-(n)- propylphenyl ) ethanamine ; (66) Methylone; 3,4-Methylenedioxy-N-methylcathinone; (67) Aminorex (2-amino-5-phenyl-2-oxazoline); (68) Pentedrone ; (69) 4-FMC or flephedrone ; 4-fluro-N-methylcathinone; (70) (3-FMC); 3-fluro-N-methylcathinone; (71) (3-MMC); 3-methylmethcathinone; (72) (3,4 DMMC); 3,4-Dimethylmethcathinone; (73) (3-MEC); 3-Methyl-N-ethylcathinone; (74) 4-methylbuphedrone or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one (75) (4 MTA); 4-methylthioamphetamine; (76) (5-Me MDA); 5-methyl-3,4-methylenedioxyamphetamine; (77) (6-APB); 6-benzofuran; (78) (PMA); 4-methoxyamphetamine; (79) (2C-B); 2,5-dimethoxy-4-bromophenethylamine; (80) (2C-C); 2,5-dimethoxy-4-chlorophenethylamine; (81) (2C-D); 4-methyl-2,5-dimethoxyphenethylamine; (82) (2C-E, aquarust , cindy ); 2,5-dimethoxy-4-ethylphenethylamine; (83) (2C-G); 3,4-dimethyl-2,5-dimethoxyphenethylamine; (84) (2C-I); 2,5-dimethoxy-4-iodophenethylamine; (85) (2C-T21); 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl] ethanamine ; (86) (2C-B-FLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- yl) ethanamine ; (87) Bromo- DragonFLY or 3C-Bromo-Dragonfly or DOB- Dragonfly ; 1-(4-Bromofuro[2,3-f][1]benzofuran-8- yl)propan -2-amine; (88) (DOB); 2,5-Dimethoxy-4-bromoamphetamine; (89) (DOC); 2,5-Dimethoxy-4-chloroamphetamine; (90) (DOM); 2,5-Dimethoxy-4-methylamphetamine; (91) (TMA2); 2,4,5-trimethoxyamphetamine; (92) (TMA6); 2,4,6-trimethoxyamphetamine; (93) (MDAT); 6,7-methylenedioxy-2-aminotetralin; (94) (4-acetoxy DiPT , ipracetin ); 4-acetoxy-N,N-diisopropyltryptamine; (95) (4-acetoxy DMT, psilacetin ;) O- Acetylpsilocin ; (96) 4-HO MET, metocin ; 4-hydroxy-N-methyl-N-ethyltryptamine; (97) 4-HO MiPT , hats ; 4-hydroxy-N-methyl-N-isopropyltryptamine; (98) 5-MeO-aMT, Alpha-O; 5-methoxy- α - methyltryptamine ; (99) (5-MeO-MiPT); N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine; (100) (DiPT); N,N-diisopropyltryptamine; (101) (DPT); dipropyltryptamine; (102) (5-MeO-DALT); N,N -diallyl-5-methoxytryptamine; (103) (3-MeO PCP); 3-methoxyphencyclidine; (104) (4-MeO PCP); 4-methoxyphencyclidine; (105) (MK-801); dizocilpine; (106) (PCE, perchloroethylene, perchloroethene ), Perc; tetrachloroethylene; (107) (PCE, perchloroethylene, perchloroethene ), Perc; tetrachloroethylene; (108) ( PCPr ); phencyclamine , N-(1-phenylcyclohexyl) propanamine ; (109) (Tenocyclidine); 1-(1-(2-thienyl)cyclohexyl)piperidine (110) (3-MeO PCE); 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl) cyclohexanamine ; (111) (ETH-LAD); 6-ethyl-6-nor-lysergic acid diethylamide; (112 (AL-LAD); 6-allyl-6-nor-LSD; (113) (PRO-LAD); 10-didehydroergoline-8-carboxamide; (114) ((1-(1,3-benzodioxol-5-yl)-2-( ethylamino )pentan-1-one, N- ethylpentylone ); (115) (MPHP), 4´-methyl-alpha-pyrrolidinohexiophenone; (116) 4'-chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP; 4'-chloro-α- pyrrolidinopentiophenone ); (117) 4-methyl-alpha-ethylaminopentiophenone (4-MEAP; 2-( ethylamino )-1-(4-methylphenyl)pentan-1-one); (118) Alpha- pyrrolidinoheptaphenone (PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); (119) Alpha- pyrrolidinohexanophenone (α-PHP; α- pyrrolidinohexanophenone ; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (120) N- ethylhexedrone (α- ethylaminohexanophenone ; 2-( ethylamino )-1- phenylhexan-1-one); (121) Methoxetamine; 2-( ethylamino )-2-(3-methoxyphenyl)cyclohexan-1-one; 2-(3-methoxyphenyl)-2-(N- ethylamino )cyclohexanone; MXE).
16.19.20.65(F) NMAC · Schedule I material containing listed substancesOFFICIAL
Instrument
Schedule I material containing listed substances
Source
https://www.srca.nm.gov/parts/title16/16.019.0020.html
Retrieved
2026-11-01
Fingerprint
7ee5271726bf25f5
F.
Any material, compound, mixture or preparation which

contains any quantity of the following substances.
(1)
3, 4-methylenedioxymethamphetamine (MDMA), its optical,

positional and geometric isomers, salts and salts of isomers;
(2)
(MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its

optical isomers, salts, and salts of isomers;
(3)
1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its

optical isomers, salts and salts of isomers;
(4)
Cathinone;
(5)
Methcathinone;
(6)
Tianeptene
;
(7)
Para
-
Methoxymethamphetamine
(PMMA)
Show 6 more laws on file
16.19.20.67(C) NMAC · Schedule III, depressantsOFFICIAL
Instrument
Schedule III, depressants
Source
https://www.srca.nm.gov/parts/title16/16.019.0020.html
Retrieved
2026-10-31
Fingerprint
9ae93256447a60a4
DEPRESSANTS: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system. (1) Any compound, mixture or preparation containing: (a) A mobarbital; (b) S ecobarbital; (c) P entobarbital; (d) B utalbital; or any salt thereof and one or more active medicinal ingredients which are not listed in any schedule. (2) Any suppository dosage form containing: (a) A mobarbital; (b) S ecobarbital; (c) P entobarbital; or any salt of any of these drugs approved by the FDA for marketing only as a suppository. (3) Any substance which contains any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid. (4) Chlorhexadol; (5) Lysergic Acid; (6) Lysergic Acid Amide; (7) Methyprylon; (8) Sulfondiethylmethane ; (9) Sulfonethylmethane ; (10) Sulfonmethane ; (11) Telazol ; Tiletamine/zolazepam; (12) Ketamine Hydrochloride. (13) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug and Cosmetic Act. (14) Embutramide; (15) Dronabinol (synthetic) in sesame oil and encapsulated in soft gelatin capsules in a drug product approved by the U.S. food and drug administration. (16) Perampanel .
Laws 2025, ch. 73 (SB 219), Sec. 5 (Medical Psilocybin Act, exemption from criminal and civil penalties) · Exemption from criminal and civil penalties for the medical use of psilocybinOFFICIAL
Instrument
Exemption from criminal and civil penalties for the medical use of psilocybin
Source
https://www.nmlegis.gov/Sessions/25%20Regular/final/SB0219.pdf
Retrieved
2026-10-31
Fingerprint
0e5616bc51b705e8
SECTION 5. EXEMPTION FROM CRIMINAL AND CIVIL PENALTIES
FOR THE MEDICAL USE OF PSILOCYBIN.--
A. A producer, clinician or qualified patient
shall not be subject to arrest, prosecution or penalty for
participating in the program.
B. The following conduct is lawful and shall not
constitute grounds for detention, search or arrest of a
person or for a violation of probation or parole, and
psilocybin that relates to the conduct is not contraband or
subject to seizure or forfeiture pursuant to the Controlled
Substances Act or the Forfeiture Act:
SJC/SB 219
Page 4
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
(1) a producer or clinician possessing or
transporting not more than an adequate supply of psilocybin
for medical purposes as defined by department rule; and
(2) a clinician administering or a qualified
patient taking psilocybin in an approved setting in
accordance with the Medical Psilocybin Act or rules
promulgated in accordance with that act.
C. A clinician shall not be subject to arrest or
prosecution or denied any right or privilege for recommending
the program or providing medical services authorized in the
Medical Psilocybin Act.
D. A person shall not be subject to arrest or
prosecution for a psilocybin-related offense for simply being
in the presence of the medical use of psilocybin as allowed
under the provisions of the Medical Psilocybin Act.
E. The Medical Psilocybin Act does not apply to
federal food and drug administration-approved clinical
trials.
NMSA 1978 30-31-2(G) to (U) (Laws 2021, 1st S.S., ch. 4, Sec. 63) · Controlled Substances Act - Definitions - controlled substance analogOFFICIAL
Instrument
Controlled Substances Act - Definitions - controlled substance analog
Source
https://www.nmlegis.gov/Sessions/21%20Special/final/HB0002.pdf
Retrieved
2026-10-29
Fingerprint
9ff1aac251ce89a2
G.  "deliver" means the actual, constructive or

attempted transfer from one person to another of a controlled

substance or controlled substance analog, whether or not

there is an agency relationship;

H.  “dispense” means to deliver a controlled

substance to an ultimate user or research subject pursuant to

the lawful order of a practitioner, including the

administering, prescribing, packaging, labeling or

compounding necessary to prepare the controlled substance for

21

that delivery;

22

23

24

25

I.  “dispenser” means a practitioner who dispenses

and includes hospitals, pharmacies and clinics where

controlled substances are dispensed;

J.  "distribute" means to deliver other than by

HB 2/a
Page 136

1

administering or dispensing a controlled substance or

2

controlled substance analog;

3

K.  "drug" or “substance” means substances

4

recognized as drugs in the official United States

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

pharmacopoeia, official homeopathic pharmacopoeia of the

United States or official national formulary or any

respective supplement to those publications.  It does not

include devices or their components, parts or accessories;

L.  “manufacture” means the production,

preparation, compounding, conversion or processing of a

controlled substance or controlled substance analog by

extraction from substances of natural origin or independently

by means of chemical synthesis or by a combination of

extraction and chemical synthesis and includes any packaging

or repackaging of the substance or labeling or relabeling of

its container, except that this term does not include the

preparation or compounding of a controlled substance:

(1)  by a practitioner as an incident to

administering or dispensing a controlled substance in the

course of the practitioner’s professional practice; or

(2)  by a practitioner, or by the

practitioner’s agent under the practitioner’s supervision,

for the purpose of or as an incident to research, teaching or

chemical analysis and not for sale;

M.  "narcotic drug" means any of the following,

HB 2/a
Page 137

1

whether produced directly or indirectly by extraction from

2

substances of vegetable origin or independently by means of

3

chemical synthesis or by a combination of extraction and

4

chemical synthesis:

5

6

7

8

9

10

11

12

(1)  opium and opiate and any salt, compound,

derivative or preparation of opium or opiate;

(2)  any salt, compound, isomer, derivative

or preparation that is a chemical equivalent of any of the

substances referred to in Paragraph (1) of this subsection,

except the isoquinoline alkaloids of opium;

(3)  opium poppy and poppy straw, including

all parts of the plant of the species Papaver somniferum L.

13

except its seeds; or

14

15

16

17

18

19

20

21

22

23

24

25

(4)  coca leaves and any salt, compound,

derivative or preparation of coca leaves, any salt, compound,

isomer, derivative or preparation that is a chemical

equivalent of any of these substances except decocainized

coca leaves or extractions of coca leaves that do not contain

cocaine or ecgonine;

N.  “opiate” means any substance having an

addiction-forming or addiction-sustaining liability similar

to morphine or being capable of conversion into a drug having

addiction-forming or addiction-sustaining liability.

“Opiate” does not include, unless specifically designated as

controlled under Section 30-31-5 NMSA 1978, the

HB 2/a
Page 138

1

dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its

2

salts, dextromethorphan.  “Opiate” does include its racemic

3

and levorotatory forms;

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

O.  "person" means an individual, partnership,

corporation, association, institution, political subdivision,

government agency or other legal entity;

P.  “practitioner” means a physician, certified

advanced practice chiropractic physician, doctor of oriental

medicine, dentist, physician assistant, certified nurse

practitioner, clinical nurse specialist, certified nurse-

midwife, prescribing psychologist, veterinarian, euthanasia

technician, pharmacist, pharmacist clinician or other person

licensed or certified to prescribe and administer drugs that

are subject to the Controlled Substances Act;

Q.  "prescription" means an order given

individually for the person for whom is prescribed a

controlled substance, either directly from a licensed

practitioner or the practitioner’s agent to the pharmacist,

including by means of electronic transmission, or indirectly

by means of a written order signed by the prescriber, bearing

the name and address of the prescriber, the prescriber’s

license classification, the name and address of the patient,

the name and quantity of the drug prescribed, directions for

use and the date of issue and in accordance with the

Controlled Substances Act or rules adopted thereto;

HB 2/a
Page 139

1

R.  "scientific investigator" means a person

2

registered to conduct research with controlled substances in

3

the course of the person’s professional practice or research

4

and includes analytical laboratories;

5

6

7

8

9

S.  "ultimate user" means a person who lawfully

possesses a controlled substance for the person’s own use or

for the use of a member of the person’s household or for

administering to an animal under the care, custody and

control of the person or by a member of the person’s

10

household;

11

12

13

14

15

16

17

18

19

20

21

T.  "drug paraphernalia" means, except as to use in

accordance with the Cannabis Regulation Act or the Lynn and

Erin Compassionate Use Act, all equipment, products and

materials of any kind that are used, intended for use or

designed for use in planting, propagating, cultivating,

growing, harvesting, manufacturing, compounding, converting,

producing, processing, preparing, testing, analyzing,

packaging, repackaging, storing, containing, concealing,

injecting, ingesting, inhaling or otherwise introducing into

the human body a controlled substance or controlled substance

analog in violation of the Controlled Substances Act.  It

22

includes:

23

24

25

(1)  kits used, intended for use or designed

for use in planting, propagating, cultivating, growing or

harvesting any species of plant that is a controlled

HB 2/a
Page 140

1

substance or controlled substance analog or from which a

2

controlled substance can be derived;

3

4

5

(2)  kits used, intended for use or designed

for use in manufacturing, compounding, converting, producing,

processing or preparing controlled substances or controlled

6

substance analogs;

7

8

9

10

11

12

13

14

15

16

17

18

19

20

(3)  isomerization devices used, intended for

use or designed for use in increasing the potency of any

species of plant that is a controlled substance;

(4)  testing equipment used, intended for use

or designed for use in identifying or in analyzing the

strength, effectiveness or purity of controlled substances or

controlled substance analogs;

(5)  scales or balances used, intended for

use or designed for use in weighing or measuring controlled

substances or controlled substance analogs;

(6)  diluents and adulterants, such as

quinine hydrochloride, mannitol, mannite dextrose and

lactose, used, intended for use or designed for use in

cutting controlled substances or controlled substance

21

analogs;

22

23

24

(7)  blenders, bowls, containers, spoons and

mixing devices used, intended for use or designed for use in

compounding controlled substances or controlled substance

25

analogs;

HB 2/a
Page 141

1

(8)  capsules, balloons, envelopes and other

2

containers used, intended for use or designed for use in

3

packaging small quantities of controlled substances or

4

controlled substance analogs;

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

(9)  containers and other objects used,

intended for use or designed for use in storing or concealing

controlled substances or controlled substance analogs;

(10)  hypodermic syringes, needles and other

objects used, intended for use or designed for use in

parenterally injecting controlled substances or controlled

substance analogs into the human body;

(11)  objects used, intended for use or

designed for use in ingesting, inhaling or otherwise

introducing cocaine into the human body, such as:

(a)  metal, wooden, acrylic, glass,

stone, plastic or ceramic pipes, with or without screens,

permanent screens, hashish heads or punctured metal bowls;

(b)  water pipes;

(c)  carburetion tubes and devices;

(d)  smoking and carburetion masks;

(e)  miniature cocaine spoons and

22

cocaine vials;

23

24

25

(f)  chamber pipes;

(g)  carburetor pipes;

(h)  electric pipes;

HB 2/a
Page 142

1

2

3

4

5

6

7

(i)  air-driven pipes;

(j)  chilams;

(k)  bongs; or

(l)  ice pipes or chillers; and

(12)  in determining whether an object is

drug paraphernalia, a court or other authority should

consider, in addition to all other logically relevant

8

factors, the following:

9

10

11

12

13

14

15

16

17

18

anyone in control of the object concerning its use;

(a)  statements by the owner or by

(b)  the proximity of the object, in

time and space, to a direct violation of the Controlled

Substances Act or any other law relating to controlled

substances or controlled substance analogs;

controlled substances or controlled substance analogs;

(c)  the proximity of the object to

controlled substance or controlled substance analog on the

(d)  the existence of any residue of a

19

object;

20

21

22

23

24

25

provided with the object concerning its use;

(e)  instructions, written or oral,

(f)  descriptive materials accompanying

the object that explain or depict its use;

(g)  the manner in which the object is

displayed for sale; and

HB 2/a
Page 143

1

2

use;

(h)  expert testimony concerning its

3

U.  “controlled substance analog” means a substance

4

other than a controlled substance that has a chemical

5

6

7

8

9

structure substantially similar to that of a controlled

substance in Schedule I, II, III, IV or V or that was

specifically designed to produce effects substantially

similar to that of controlled substances in Schedule I, II,

III, IV or V.  Examples of chemical classes in which

10

controlled substance analogs are found:

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

(1)  include:

(a)  phenethylamines;

(b)  N-substituted piperidines;

(c)  morphinans;

(d)  ecgonines;

(e)  quinazolinones;

(f)  substituted indoles; and

(g)  arylcycloalkylamines; and

(2)  do not include those substances that are

generally recognized as safe and effective within the meaning

of the Federal Food, Drug, and Cosmetic Act or have been

manufactured, distributed or possessed in conformance with

the provisions of an approved new drug application or an

exemption for investigational use within the meaning of

Section 505 of the Federal Food, Drug, and Cosmetic Act;
NMSA 1978 Sec. 30-29-2 · Glue; aerosol spray; abuse or possession for abuse; penaltyOFFICIAL
Instrument
Glue; aerosol spray; abuse or possession for abuse; penalty
Source
https://nmonesource.com/nmos/nmsa/en/4371/1/document.do
Retrieved
2026-10-31
Fingerprint
e8dce1d6980dd27e
A. No person shall intentionally smell, sniff or inhale the fumes or vapors from a
      glue, aerosol spray product or other chemical substance for the purpose of causing
      a condition of or inducing symptoms of intoxication, elation, euphoria, dizziness,
      excitement, irrational behavior, exhilaration, stupefaction or dulling of the senses,
      or for the purpose of in any manner changing, distorting or disturbing the audio,
      visual or mental processes.

B. No person shall intentionally possess a glue, aerosol spray product or other chemical
      substance for any purpose set forth in Subsection A of this section.

C. As used in this section, "glue" means what is commonly referred to as plastic or
      model airplane cement and includes any cement containing hexane, benzene, toluene,
      xylene, carbon tetrachloride, chloroform, ethylene dichloride, acetone, cyclohexanone,
      methyl ethyl ketone, methylisobutyl ketone, amyl acetate, butyl acetate, ethyl acetate,
      tricresyl phosphate, butyl alcohol, ethyl alcohol, isopropyl alcohol or methylcellosolve
      acetate.

D. The provisions of this section do not apply to any aerosol spray product or other
      chemical substance used for legitimate medicinal purposes and obtained either on a
      prescription basis or for medicinal purposes by a person over the age of eighteen.

E. Any person who violates any provision of this section is guilty of a misdemeanor.  The sentence or fine may be waived in the discretion of the court in the case of
      any person who has not been previously convicted of violating this section and who
      has successfully completed a drug education or treatment program approved by the court.
NMSA 1978 Sec. 30-31-2(U) · Controlled substance analog definitionOFFICIAL
Instrument
Controlled substance analog definition
Source
https://nmonesource.com/nmos/nmsa/en/4371/1/document.do
Retrieved
2026-11-01
Fingerprint
91a1298334575cee
U. “controlled substance analog” means a substance other than a controlled
substance that has a chemical structure substantially similar to that of a controlled
substance in Schedule I, II, III, IV or V or that was specifically designed to produce
effects substantially similar to that of controlled substances in Schedule I, II, III, IV or V.
Examples of chemical classes in which controlled substance analogs are found:

       (1)      include:

             (a) phenethylamines;

             (b) N-substituted piperidines;

             (c) morphinans;

             (d) ecgonines;

             (e) quinazolinones;

             (f) substituted indoles; and

             (g) arylcycloalkylamines; and

        (2)    do not include those substances that are generally recognized as safe and
effective within the meaning of the Federal Food, Drug, and Cosmetic Act or have been
manufactured, distributed or possessed in conformance with the provisions of an
approved new drug application or an exemption for investigational use within the
meaning of Section 505 of the Federal Food, Drug, and Cosmetic Act;
NMSA 1978, Sec. 30-29-2 · Glue; aerosol spray; abuse or possession for abuse; penaltyOFFICIAL
Instrument
Glue; aerosol spray; abuse or possession for abuse; penalty
Source
https://nmonesource.com/nmos/nmsa/en/4371/1/document.do
Retrieved
2026-10-31
Fingerprint
930e136b15c7e277
30-29-2. Glue; aerosol spray; abuse or possession for abuse;
penalty.
   A. No person shall intentionally smell, sniff or inhale the fumes or vapors from a
glue, aerosol spray product or other chemical substance for the purpose of causing a
condition of or inducing symptoms of intoxication, elation, euphoria, dizziness,
excitement, irrational behavior, exhilaration, stupefaction or dulling of the senses, or for
the purpose of in any manner changing, distorting or disturbing the audio, visual or
mental processes.

   B. No person shall intentionally possess a glue, aerosol spray product or other
chemical substance for any purpose set forth in Subsection A of this section.

     C. As used in this section, "glue" means what is commonly referred to as plastic or
model airplane cement and includes any cement containing hexane, benzene, toluene,
xylene, carbon tetrachloride, chloroform, ethylene dichloride, acetone, cyclohexanone,
methyl ethyl ketone, methylisobutyl ketone, amyl acetate, butyl acetate, ethyl acetate,
tricresyl phosphate, butyl alcohol, ethyl alcohol, isopropyl alcohol or methylcellosolve
acetate.
   D. The provisions of this section do not apply to any aerosol spray product or other
chemical substance used for legitimate medicinal purposes and obtained either on a
prescription basis or for medicinal purposes by a person over the age of eighteen.

   E. Any person who violates any provision of this section is guilty of a misdemeanor.
The sentence or fine may be waived in the discretion of the court in the case of any
person who has not been previously convicted of violating this section and who has
successfully completed a drug education or treatment program approved by the court.

History: Laws 1979, ch. 82, § 1.

Ibogaine in neighboring states

Ibogaine in 45 other states

Closest to Ibogaine in New Mexico

Same framework in New Mexico

23 other compounds in New Mexico

Cite this page

Compound Analytics. "Is Ibogaine Legal in New Mexico? Updated Nov 2026." Compound Laws, https://compoundlaws.com/compounds/ibogaine/new-mexico/. Accessed November 13, 2026.

Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.

About · Methodology · Glossary · Changes · RSS · Data licensing · llms.txt · Sitemap